This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GSK659032, SB-659032
Description: Rilapladib is a small molecule inhibitor of Lp-PLA2 and a backup compound to darapladib. High plasma lipoprotein phospholipase A2 activity (Lp-PLA2) has been reported to be a risk factor for dementia.
Deal Structure: This small molecule was discovered by GlaxoSmithKline, using Human Genome Sciences technology. Under the terms of an agreement signed in 1993, HGSI is entitled to receive clinical development milestone payments and royalties for compounds discovered by GlaxoSmithKline through the use of HGSI's technology and intellectual property. HGSI is entitled to receive a milestone payment if Rilapladib moves through clinical development into registration and HGSI will receive royalties of up to 10% of worldwide net sales if a compound is commercialized. In addition, HGSI has an option to co-promote up to 20% in North America and Europe.
In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.
Pink Sheet Beyond Bapi: Alzheimer’s Pipeline Runs Deep
Additional information available to subscribers only: